Probably not, if the prescription is for weight loss. The 2025 national benefits survey found that large firms offering health benefits covered GLP-1 agonists for weight loss at a rate of 19% against 81% that did not [1]. That single split is why most readers arriving here meet a checkout rather than a formulary, and why the figures in what a GLP-1 actually costs per month are the ones that decide anything.
What the 19% is counting
The denominator deserves attention before the number travels anywhere. It is large firms that offer health benefits, and it is coverage for weight loss specifically, which is a narrower question than whether a plan covers the molecule at all. Coverage when semaglutide or tirzepatide is prescribed for type 2 diabetes is an older and far broader arrangement, and it is governed by a different part of the formulary.
Two people can be prescribed the identical drug at the identical dose and meet completely different bills, because the indication written on the prescription decides which rule applies. That is the mechanism behind the cash market, and it is the reason a telehealth seller quotes a cash price by default.
The surrounding numbers explain the direction
The same survey recorded an average annual family premium of $26,993, up $1,408 or 6% in a single year. Covered workers contributed 16% of the single-coverage premium, averaging $1,440, and 26% of family coverage, averaging $6,850. Among workers with a general annual deductible for single coverage, that deductible averaged $1,886.
Asked what was pushing premiums up, 36% of large firms named prescription drug prices as contributing a great deal. Another 45% of firms offering benefits reported that their employees had a high or moderate level of concern about affording their cost sharing. An employer market already under that pressure is deciding whether to add a drug class that is expensive by design, which is not the setting in which 19% becomes a majority quickly.
Why insured people report far higher coverage
A survey of 518 full-time employed US adults who were starting tirzepatide found that 80.9% had employer-provided insurance, and among those, 55.9% reported that it covered obesity medications [2]. Set against the employer-side figure of 19%, that looks like a contradiction, and it is not one.
Everyone in that sample had already managed to start the drug, and having coverage is one of the main reasons a person manages that. The survey is describing the people who got through the gate rather than everybody who walked up to it. The ones who did not get through, and what stopped them, are counted in the people offered a prescription who declined it.
What an employer is actually weighing
The retention figure is the one a benefits committee reads twice. A little over half of those respondents, 52.3%, said they would consider changing jobs in order to obtain coverage for obesity medication, and 81.7% said such coverage could increase job satisfaction. Whether a stated intention survives contact with a real job offer is a separate question, and a benefit that half a workforce segment would move for is priced differently from one nobody notices.
The same survey carried a work productivity and impairment measure, which is the thread that converts a benefit cost into an operational one. It is baseline data from a longitudinal study, so whether those impairment scores move is the informative half and it has not been reported yet.
Coverage, not price, is what moves volume
In March 2024 the FDA widened Wegovy’s label to include reducing cardiovascular events, and Medicare Part D began covering it for that indication. National prescription data show Wegovy fills rising 136.4% against the period before, and rising 598.1% through Part D specifically, off a base close to zero [3]. A segmented regression attributes an estimated 592,624 additional fills to the policy change by September 2024.
The list price did not move. What moved was who else would pay it, which is the same mechanism described in covered and still not treated. Each new outcome indication is a potential unlock for the group that has the condition, and a non-event for everybody else.
What to ask, and who decides
Coverage is worth asking about directly rather than assumed absent, since more than half of those insured respondents had it. The decision sits with the plan sponsor and is written into the formulary, not with the prescriber, and formulary rules change more often than employees check them. Human resources holds the plan documents, and the exclusion, where one exists, is usually written as a weight-loss exclusion rather than a drug-name one.
If the answer is no, the published price becomes the whole question, and the useful follow-up is whether it is the whole price. What a plan still charges when it does cover the drug is set out in what insurance coverage costs, and how long the approval itself takes is in the prior authorization timeline.